Posted by Michael Wonder on 19 Sep 2022
FDA grants Radiopharm Theranostics DUNP19 product rare paediatric disease designation
16 September 2022 - Radiopharm Theranostics has been granted rare paediatric disease designation by the US FDA for its DUNP19 technology.
The company’s product is designed to treat bone cancer in children, and the designation means Radiopharm will receive a priority review voucher, which can be used to expedite approval of the technology.
